BioOncology Watch

Timely Information for Practicing Physicians

 

FEBRUARY 2000

Non-Hodgkin’s Lymphoma (NHL)

Radioimmunotherapy (RIT) with IDEC-Y2B8.   IDEC-Y2B8 (IDEC Pharmaceuticals Corp.)  consists of a murine anti-CD20 monoclonal antibody, ibritumomab, covalently bound to tiuxetan to which the radioisotope yttrium-90 is chelated.  Thomas Witzig and colleagues conducted a multicenter phase I/II study (n=51) of unlabeled rituximab followed by IDEC-Y2B8 treatment in relapsed/refractory NHL patients.  Rituximab was given prior to RIT to clear peripheral blood B-lymphocytes to optimize biodistribution of the radiolabeled antibody.  pre-RIT dosing with rituximab at 250 mg/m2 was well-tolerated and the maximum-tolerated single dose of IDEC-Y2B8 that can be administered in the outpatient setting without stem-cell support is 0.4 mCi/kg.  The principal side effect was reversible hematologic toxicity and only one patient developed an anti-antibody response (human antichimeric antibody/human antimouse antibody).  This trial shows that RIT can be administered safely and effectively in the outpatient setting.  (Witzig TE, et al.  J Clin Oncol 1999; 17: 3793-3803)

 

Acute Graft-Versus-Host Disease (GVHD)

Treatment with daclizumab.  Daclizumab (Hoffman-LaRoche, Inc.) is a humanized monoclonal antibody directed against the a chain of the interleukin-2 receptor (IL-2R).  The interaction of IL-2 and IL-2R enhances lymphocyte proliferation and differentiation; previous studies have shown the blockade of IL-2R to abrogate acute GVHD.  D. Przepiorka and coworkers treated patients with advanced or steroid-refractory GVHD with daclizumab 1mg/kg on either days 1,8,15,22,29 (n=24) or days 1,4,8,15,22 (n=19).  The CR rate (achievement of stage 0 GVHD) on day 43 was 29% and 47% for the first and second groups, respectively.  Day 120 survival was 29% and 53%, respectively.  There were no infusion-related reactions and no serious side effects reported.  Daclizumab is an active agent for the treatment of acute GVHD and the second regimen has been recommended for further studies.  (Przepiorka D, et al.  Blood 2000; 95: 83-89)

 

Chronic Myelogenous Leukemia (CML)

Molecular heterogeneity in cytogenetic responders.  Andreas Hochhaus et al. utilized a reverse transcriptase polymerase chain reaction (RT-PCR) assay to quantify levels of BCR-ABL transcripts in peripheral blood from 54 CML patients with a complete cytogenetic response to interferon-a therapy.  All 54 patients had molecular evidence of residual BCR-ABL transcripts and the results were expressed as a BCR-ABL/ABL ratio.  The median BCR-ABL/ABL ratio at maximal response of 14 patients who were observed to relapse was greater than in those who remained in complete cytogenetic remission (0.49% vs. 0.021%, P<0.0001).  These findings show that molecular evidence of disease is rarely if ever eliminated and that the level of molecular minimal residual disease correlates with the risk for relapse.  The authors suggested that interferon-a be continued at least until low levels of residual disease are achieved in CML patients who have a complete cytogenetic response.  (Hochhaus A, et al.  Blood 2000; 95: 62-66)

 

Donor lymphoctye infusion (DLI) administration and GVHD.  F Dazzi and colleagues compared the results and GVHD incidence for CML patients relapsing after allogeneic stem cell transplantation who were treated with DLI administered as a single bulk dose regimen (BDR) (n=28) versus a multiple escalating dose regimen (EDR) (n=20).  The median interval between EDR doses was 20 weeks (range, 12-33 weeks).  The complete cytogenetic remission rate was similar for the BDR group compared to the EDR group (67% vs. 91%, P=0.70).  However, the incidence of GVHD was higher in the BDR patients than in the EDR patients (44% vs. 10%, P<0.011).  In addition, an analysis of BDR and EDR patients who received comparable total lymphocyte doses confirmed the reduced GVH risk in the EDR group.  These results indicate that DLI administered as an EDR decreases the risk for GVHD and maintains effectiveness in the treatment of CML patients in relapse.  (Dazzi F, et al.  Blood 2000; 95: 67-71)

 

Effects of interferon-a (IFN) therapy on allogeneic bone marrow transplantation (BMT) outcomes.  IFN is increasingly used as initial therapy for CML.  Two recent studies have assessed the effect of prior IFN treatment on the outcome of allogeneic BMT in CML patients.  Rudiger Hehlmann and colleagues in the German CML Study Group reviewed data from 197 CML patients who underwent BMT.  Outcomes after BMT were similar for patients who received pretreatment IFN compared to those who received pretreatment chemotherapy.  Survival was not affected by duration of IFN therapy, however, 5-year survival was found to be 46% for 50 patients who received IFN within that last 90 days before BMT and 71% for 36 patients who did not (P=0.0057).  No differences in causes of death were found between these two patient groups.  In a second study, Sergio Geralt et al. reviewed data from the International Bone Marrow Transplant Registry and observed no differences in survival or leukemia-free survival for CML patients who received a short course (median of 2 months) of IFN before BMT (n=209) compared to those who received hydroxyurea before BMT (n=664).  No data on IFN use within 90 days of BMT was reviewed in this study.  These studies indicate that clinical outcomes after BMT are not compromised by prior IFN therapy. However, the finding by Hehlmann et al. that patients receiving IFN within 90 days of BMT may have a poorer 5-year survival suggests the need for further investigation to determine optimal timing of IFN therapy.  (Hehlmann R, et al.  Blood 1999; 94: 3668-3677 and Giralt S, et al. Blood 2000; 95: 410-415)

Return to Archive

Produced by Market Development Group through an educational grant from Genentech, Inc. and IDEC Pharmaceuticals. Comments and inquiries can be e-mailed to webmaster@biooncologywatch.org